Healthcare Services

Global Necrobiosis Lipodica (NL) Market Revenue Expected To Reach $5.95 Billion By 2030

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Necrobiosis Lipodica (NL) Market By 2030 Based On Its 2026 Value?

The necrobiosis lipodica (nl) market size has shown robust growth over recent years. It is forecast to increase from $4.35 billion in 2025 to $4.64 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. The growth observed historically is linked to the rising prevalence of diabetes-related skin disorders, the growing number of diagnoses made through skin biopsy, the common reliance on corticosteroid-based therapies, restricted access to specialized dermatology care, and the gradual adoption of advanced wound care products.

The market for necrobiosis lipodica (nl) is projected to experience substantial expansion over the coming years. This market is anticipated to reach $5.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.4%. Several factors will drive this growth during the forecast period, including an increasing demand for biologics and immunomodulators, the proliferation of regenerative medicine solutions, wider access to laser and phototherapy devices, escalating investment in dermatology clinical research, and the creation of combination therapeutic protocols. Key trends anticipated during the same period encompass the growing application of phototherapy and laser-based treatments, increasing integration of advanced wound care and compression therapies, a developing preference for topical and systemic immunomodulators, a heightened emphasis on early skin biopsy and precise differential diagnosis, and the broadening of regenerative medicine uses, such as stem cell therapy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22066&type=smp

What Are The Main Drivers Accelerating The Growth Of The Necrobiosis Lipodica (NL) Market?

The increasing instances of diabetes are anticipated to boost the necrobiosis lipoidica (NL) market moving forward. Diabetes is a long-term condition where the body struggles to manage blood sugar levels, either due to insufficient insulin production or resistance, which can lead to various health complications. The rise in diabetes cases is attributed to sedentary lifestyles, unhealthy eating habits, and genetic predispositions. Modern living often involves prolonged sitting, reduced physical activity, and excessive screen time, contributing to obesity and insulin resistance. High blood sugar in diabetes damages small blood vessels (microangiopathy), resulting in poor circulation. This limits oxygen and nutrient supply to the skin, making it more vulnerable to injury and delaying healing. The degeneration of skin tissue then contributes to the development of the characteristic yellowish, atrophic plaques seen in NL. For instance, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%. Concurrently, the percentage achieving target HbA1c levels rose to 37.9%, which was the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing number of diabetes cases is a key driver for the necrobiosis lipoidica (NL) market. The growing prevalence of autoimmune diseases is projected to stimulate the growth of the necrobiosis lipoidica market in the future. Autoimmune diseases are conditions where the body’s immune system mistakenly attacks its own healthy cells and tissues. The rising incidence of autoimmune diseases is fueled by factors such as genetic predispositions, environmental triggers, and changes in lifestyle and immune system behavior. These conditions contribute to necrobiosis lipoidica (NL) by triggering chronic inflammation and immune system dysfunction, which can lead to collagen degradation and impaired skin healing. For example, in September 2025, according to WeCovr, a UK-based insurance comparison platform, it is projected that more than 3.5 million people in the United Kingdom will be living with an autoimmune disease by the close of 2025. Hence, the higher incidence of autoimmune diseases is driving the expansion of the necrobiosis lipoidica market.

How Is The Necrobiosis Lipodica (NL) Market Structured Across Different Market Segments?

The necrobiosis lipodica (nl) market covered in this report is segmented –

1) By Treatment: Therapy, Drugs, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations

3) By Diagnosis: Skin Biopsy, Histopathology, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Therapy: Phototherapy, Laser Therapy, Wound Care And Compression Therapy, Physical Therapy And Rehabilitation

2) By Drugs: Topical Corticosteroids, Intralesional Corticosteroids, Systemic Corticosteroids, Immunomodulators, Biologics, Antiplatelet Agents, Antioxidants And Vasodilators, Antibiotics

3) By Other Treatments: Surgical Excision And Skin Grafting, Hyperbaric Oxygen Therapy (HBOT), Platelet-Rich Plasma (PRP) Therapy, Stem Cell Therapy And Regenerative Medicine, Alternative And Herbal Treatments

Leading companies in the near-patient molecular solutions market are concentrating on integrating technological advancements like isothermal nucleic acid amplification to elevate testing efficiency, portability, and diagnostic accuracy. Isothermal nucleic acid amplification represents an advanced molecular diagnostic technique that amplifies target nucleic acid sequences at a consistent temperature, thereby eliminating the necessity for thermal cycling, a requirement in conventional polymerase chain reaction (PCR), which in turn enables rapid, sensitive, and compact molecular testing. For instance, in June 2023, Cue Health Inc., a US-based healthcare technology company specializing in molecular diagnostics, secured FDA marketing authorization for the Cue COVID-19 Molecular Test, an isothermal amplification-based diagnostic device engineered for at-home and point-of-care detection of SARS-CoV-2 RNA. This system incorporates a single-use cartridge, a Bluetooth-enabled reader, and a mobile app interface that guides users through the testing procedure and delivers molecular results in about 20 minutes. The Cue COVID-19 molecular test enhances access to accurate molecular-level diagnostics, minimizes turnaround time, and facilitates real-time health decision-making outside of conventional laboratory settings.

Which Industry Players Are Present In The Necrobiosis Lipodica (NL) Market?

Major companies operating in the necrobiosis lipodica (nl) market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co Inc, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Dr. Reddys Laboratories Ltd, Incyte Pharmaceuticals, Celltrion Healthcare Co Ltd, Almirall SA, Samsung Bioepis Co Ltd, HanAll Biopharma Co Ltd, AbbVie Inc, Amgen Inc, UCB Pharma SA, LEO Pharma AS, Bristol Myers Squibb Company, Roche Holding AG, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc

Access The Complete Necrobiosis Lipodica (NL) Market Report:

https://www.thebusinessresearchcompany.com/report/necrobiosis-lipodica-nl-global-market-report

Which Region Contributes The Most To The Necrobiosis Lipodica (NL) Market?

North America was the largest region in the necrobiosis lipoidica market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrobiosis lipodica (nl) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Necrobiosis Lipodica (NL) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22066&type=smp

Browse Through More Reports Similar to the Global Necrobiosis Lipodica (NL) Market 2026, By The Business Research Company

Non Therapeutic Biomolecules Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-therapeutic-biomolecules-global-market-report

Clinical Chemistry Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-chemistry-global-market-report

Small Molecule Drug Discovery Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-molecule-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795